The Copmparison of Accuracy of PtcCO2 and in PetCO2 in COPD Patients With NIV Treatment

COPD Clinical Trial

Official title:

The Copmparison of Accuracy of PtcCO2 and in PetCO2 in COPD Patients With NIV Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04258982
• Other study ID #: GIRH-201927
• Status: Recruiting
• Start date: February 8, 2019
• Est. completion date: December 31, 2021

Study information

• Verified date: February 2021
• Source: Guangzhou Medical University
• Contact: Shanshan Zha, master
• Phone: 15013023031
• Email: zhass2011[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The chronic obstructive pulmonary disease (COPD) patients with type II respiratory failure always needs PaCO2 test to monitor the changes of disease. Method used mostly nowadays to detect PaCO2 is arterial puncture which is accurate but is invasive, painful and non-dynamic. Noninvasive measurement methods includes end-tidal CO2 (PetCO2), transcutaneous CO2 (PtcCO2) which can monitor the PaCO2 dynamically and noninvasively, but their accuracy is in controversy. Common PetCO2 is especially inaccurate in COPD patients while our team find that the accuracy can be improved by prolong expiration method (PetCO2 (P)).So the investigators want to compare the accuracy of PtcCO2 and PetCO2(P) in AECOPD patients during noninvasive ventilation(NIV).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 100 Years

Eligibility

Inclusion Criteria:

• AECOPD patients with type II respiratory failure who need NIV treatment

Exclusion Criteria:

• hemodynamics is unstable;

• any other lung disease despite COPD;

• other diseases influencing experiments: Cognitive impairment disease mouth and nose trauma.

Related Conditions & MeSH terms

• COPD

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Guangzhou Medical University.	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Zhenfeng He

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	partial arterial pressure of end-tidal CO2 measured by prolong expiration method [PetCO2(P)]	PetCO2(P) will be measured before and after NIV treatment.	2 hours
Primary	partial arterial pressure of transcutaneous CO2 (PtcCO2)	PtcCO2 will be measured before and after NIV treatment.	2 hours
Primary	partial arterial pressure of carbon dioxide (PaCO2)	PaCO2 will be measured before and after NIV treatment.	2 hours